Company · BMY
Bristol Myers Squibb
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
75
37 still marketed
Novel approvals
41
Approvals since 2021
59
Originals and new uses
Phase 3 trials
392
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Camzyos new use Priority reviewOrphanSep 30, 2026
- Zenbexus approved NovelPriority reviewOrphanAug 13, 2026
- Onureg new use OrphanApr 9, 2026
- Opdivo new use Priority reviewOrphanMar 20, 2026
- Sotyktu new use Mar 6, 2026
- Opdivo Qvantig new use Nov 24, 2025
- Opdivo Qvantig new use Oct 27, 2025
- Opdivo Qvantig new use Oct 27, 2025
- Opdivo new use Priority reviewOrphanMay 23, 2025
- Yervoy new use Priority reviewOrphanMay 23, 2025
Drugs in development (38)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- CC-99282BMS-986369, GolcadomidePhase 37 trials
Bristol Myers Squibb · Lymphoma, Follicular, Large B-cell Lymphoma, Non-Hodgkin Lymphoma
- rHuPH20Phase 35 trials
Bristol Myers Squibb · Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma
- NavlimetostatBMS-986504, MRTX1719Phase 34 trials
Bristol Myers Squibb · Pancreatic Ductal Adenocarcinoma, Metastatic Non-small Cell Lung Cancer With MTAP Deletion, Solid Tumors
- BMS-986278AdmilparantPhase 33 trials
Bristol Myers Squibb · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
- CasdatifanAB521Phase 33 trials
Arcus Biosciences, Inc. · Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma (RCC)
- Zola-celBMS-986353, CC-97540Phase 33 trials
Bristol Myers Squibb · Systemic Sclerosis, Lupus Erythematosus, Systemic, Lupus Nephritis
- Arlocabtagene AutoleucelBMS-986393, GPRC5D CAR T cellsPhase 32 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM)
- bb2121BMS-986395Phase 32 trials
Bristol Myers Squibb · Multiple Myeloma
- SitravatinibMGCD516Phase 32 trials
BeOne Medicines (BeiGene) · Advanced Malignancies, Advanced or Metastatic Solid Malignancies
- Atigotatug+NivolumabBMS-986489Phase 31 trial
Bristol Myers Squibb · Extensive-Stage Small Cell Lung Cancer
- BMS-986365Phase 31 trial
Bristol Myers Squibb · Metastatic Castration-resistant Prostate Cancer
- cendakimabCC-93538, BMS-986355Phase 31 trial
Bristol Myers Squibb · Eosinophilic Esophagitis
- valemetostat tosylateDS-3201bPhase 23 trials
Daiichi Sankyo · Non-small Cell Lung Cancer, Lung Cancer, Relapsed/Refractory Peripheral T-Cell Lymphoma
- BMS-986158Phase 22 trials
Bristol Myers Squibb · Myelofibrosis, Multiple Myeloma
- BMS-986368CC-97489Phase 22 trials
Bristol Myers Squibb · Agitation, Alzheimer Disease, Multiple Sclerosis Spasticity
- ImzokitugBMS-986340Phase 22 trials
Bristol Myers Squibb · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Cervical Cancer
- AG-120Phase 21 trial
Bristol Myers Squibb · Leukemia, Myeloid, Acute
- AG-221Phase 21 trial
Bristol Myers Squibb · Leukemia, Myeloid, Acute
- BMS-986012Phase 21 trial
Bristol Myers Squibb · Extensive-stage Small Cell Lung Cancer
- BMS-986213Phase 21 trial
Bristol Myers Squibb · Advanced Solid Tumors
- BMS-986435MYK-224Phase 21 trial
Bristol Myers Squibb · Heart Failure
- BMS-986446Phase 21 trial
Bristol Myers Squibb · Alzheimer Disease, Early Onset
Recruiting Phase 3 trials
Largest first.
- Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07116967 · 3,040 participants (planned) · Start Sep 22, 2025 · Primary completion Jan 16, 2031
Drug: Deucravacitinib; Ustekinumab · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 411 sites in all
- Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)Pivotal-lookingRecruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
NCT05980949 · 1,000 participants (planned) · Start Jul 11, 2023 · Primary completion Sep 7, 2027
Drug: KarXT · For: Psychosis Associated With Alzheimer's Disease
Sites: Homewood, Alabama; Chandler, Arizona; Gilbert, Arizona · 432 sites in all
- A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06561386 · 1,000 participants (planned) · Start Oct 7, 2024 · Primary completion Jul 30, 2030
Drug: Nivolumab; Relatlimab and 4 more · For: Non-small Cell Lung Cancer
Sites: Mobile, Alabama; Tucson, Arizona; Los Angeles, California · 330 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07221357 · 990 participants (planned) · Start Dec 31, 2025 · Primary completion Feb 2, 2030
Drug: Pumitamig; FOLFOX and 3 more · For: Untreated, Unresectable, or Metastatic Colorectal Cancer
Sites: Tucson, Arizona; Springdale, Arkansas; Los Angeles, California · 286 sites in all
- A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07361497 · 850 participants (planned) · Start Mar 16, 2026 · Primary completion Sep 18, 2030
Drug: Pumitamig; Durvalumab · For: Non-small Cell Lung Cancer (NSCLC)
Sites: Daphne, Alabama; Golden, Colorado; Newark, Delaware · 259 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07680790 · 850 participants (planned) · Start Sep 8, 2026 · Primary completion Dec 30, 2031
Drug: Iza-bren; Osimertinib and 3 more · For: Non-Small Cell Lung Cancer
Sites: Beverly Hills, California; Fullerton, California; La Jolla, California · 205 sites in all
- A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Pivotal-lookingRecruiting
CelgeneBristol Myers Squibb (BMY)
NCT05519085 · 810 participants (planned) · Start Sep 20, 2022 · Primary completion Jan 10, 2027
Drug: mezigdomide; Pomalidomide and 2 more · For: Relapsed or Refractory Multiple Myeloma
Sites: Los Alamitos, California; San Diego, California; West Hollywood, California · 266 sites in all
- A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07361510 · 750 participants (planned) · Start Mar 12, 2026 · Primary completion Oct 14, 2031
Drug: Pumitamig; Pembrolizumab · For: Non-Small Cell Lung Cancer (NSCLC)
Sites: Daphne, Alabama; Bullhead City, Arizona; Glendale, Arizona · 283 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07221149 · 690 participants (planned) · Start Mar 13, 2026 · Primary completion Nov 8, 2030
Drug: Pumitamig; Folfox and 2 more · For: Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Sites: Phoenix, Arizona; Los Angeles, California; Orange, California · 161 sites in all
- A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical TrialsPivotal-lookingRecruiting
CelgeneBristol Myers Squibb (BMY)
NCT04064060 · 665 participants (planned) · Start Aug 12, 2019 · Primary completion May 12, 2028
Drug: Luspatercept · For: Myelodysplastic Syndromes (MDS); Beta-thalassemia; Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
Sites: Los Angeles, California; Oakland, California; Stanford, California · 143 sites in all
Marketed drugs (37)
Newest FDA action first.
- Reblozyl Luspatercept-Aamt · 2019
- Sprycel Dasatinib · 2006
- Camzyos Mavacamten · 2022
- Thalomid Thalidomide · 1998
- Krazati Adagrasib · 2022
- Yervoy Ipilimumab · 2011
- Baraclude Entecavir · 2005
- Baraclude Entecavir · 2005
- Zenbexus Iberdomide Hydrochloride · 2026
- Opdivo Nivolumab · 2014
- Revlimid Lenalidomide · 2005
- Inrebic Fedratinib Hydrochloride · 2019
- Sotyktu Deucravacitinib · 2022
- Eliquis Apixaban · 2012
- Eliquis Apixaban · 2025
- Opdualag Nivolumab, Relatlimab-Rmbw · 2022
- Opdivo Qvantig Nivolumab, Hyaluronidase-Nvhy · 2024
- Pomalyst Pomalidomide · 2013
- Onureg Azacitidine · 2020
- Evotaz Atazanavir Sulfate, Cobicistat · 2015
- Idhifa Enasidenib Mesylate · 2017
- Opdivo Qvantig Nivolumab, Hyaluronidase-Nvhy · 2024
- Reyataz Atazanavir Sulfate · 2014
- Reyataz Atazanavir Sulfate · 2003
- Cobenfy Trospium Chloride, Xanomeline Tartrate · 2024
- Zeposia Ozanimod Hydrochloride · 2020
- Vidaza Azacitidine · 2004
- Augtyro Repotrectinib · 2023
- Orencia Abatacept · 2005
- Empliciti Elotuzumab · 2015
- Istodax Romidepsin · 2009
- Nulojix Belatacept · 2011
- Abraxane Paclitaxel · 2005
- Opdivo Nivolumab · 2015
- Otezla Apremilast · 2014
- Sprycel Dasatinib · 2006
- Thalomid Thalidomide · 2006
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.